Anticancer virotherapy using mutant oncolytic HSV1 vectors regulated multiple pancreatic cancer associated promoters.

Research Project

Project/Area Number	22700917
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Clinical oncology
Research Institution	Hiroshima University
Principal Investigator	FUKUDA Emi 広島大学, 自然科学研究支援開発センター, 研究員 (20403503)
Project Period (FY)	2010 – 2011
Project Status	Completed (Fiscal Year 2011)
Budget Amount *help	¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000) Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	癌 / ウイルス / ゲノム
Research Abstract	We combined the minimal promoter region of tumor specific markers(hTERT, CEA, Survivin, ERBB2 and DF3) overexpress in the pancreatic tumor and obtained six constructs those have over 20-fold-higher promoter activity than those of full length promoters. These promoter constructs were integrated to Flip-Flop HSV BAC system and generated the recombinant herpes simplex virus. These recombinant viruses were deficient in the potential of cytotoxic activity and were not sufficient level for medical treatment.

Report

(3 results)